Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
09:32 ET | 110 | 3.88 |
09:41 ET | 525 | 3.8 |
09:43 ET | 1500 | 3.86 |
09:45 ET | 700 | 3.9322 |
09:59 ET | 165 | 3.9 |
10:32 ET | 200 | 3.75 |
10:33 ET | 294 | 3.74 |
10:42 ET | 200 | 3.73 |
10:51 ET | 300 | 3.88 |
10:53 ET | 100 | 3.88 |
10:55 ET | 200 | 3.87 |
10:57 ET | 1125 | 3.89 |
11:00 ET | 325 | 3.89 |
11:04 ET | 200 | 3.89 |
11:33 ET | 300 | 3.82 |
11:36 ET | 300 | 3.85 |
11:38 ET | 300 | 3.85 |
11:40 ET | 200 | 3.85 |
11:42 ET | 601 | 3.85 |
11:44 ET | 700 | 3.9 |
11:47 ET | 849 | 3.86 |
11:49 ET | 200 | 3.85 |
12:34 ET | 257 | 3.86 |
01:12 ET | 100 | 3.82 |
01:15 ET | 200 | 3.85 |
01:50 ET | 500 | 3.8213 |
01:53 ET | 1177 | 3.8261 |
01:55 ET | 1000 | 3.8201 |
03:23 ET | 100 | 3.88 |
03:45 ET | 800 | 3.9 |
03:52 ET | 100 | 3.91 |
03:56 ET | 100 | 3.875 |
03:59 ET | 1305 | 3.93 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 214.2M | -2.1x | --- |
Candel Therapeutics Inc | 216.9M | -5.6x | --- |
Design Therapeutics Inc | 209.6M | -3.7x | --- |
Aldeyra Therapeutics Inc | 221.6M | -7.2x | --- |
Pyxis Oncology Inc | 223.2M | -2.6x | --- |
Acrivon Therapeutics Inc | 223.9M | -2.4x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $214.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.55 |
EPS | $-1.88 |
Book Value | $4.32 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.